Multicenter retrospective study evaluating the efficacy and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer.
Not Applicable
Completed
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000049194
- Lead Sponsor
- orth East Japan Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients diagnosed as having small-cell lung cancer (SCLC), combined SCLC, large-cell neuroendocrine carcinoma. (2) In both groups, patients do not meet the eligibility criteria for Durvalumab (e.g. active autoimmune disease, grade 2 or higher pneumonitis from previous CRT) (3)Patients with distant metastases at diagnosis of recurrence or at initial evaluation after chemoradiotherapy. (4)Other cases that are determined to be inappropriate by attending physicians. (5)Patients with active multiple cancers. (6) Receipt of any investigational new drugs for post-treatment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method